TIDMOBD
RNS Number : 0865U
Oxford BioDynamics PLC
31 March 2021
Oxford BioDynamics signs supply and resale agreement with
Agilent Technologies,
and launches EpiSwitch(R) Explorer Array Kit for R&D use
-- Agilent Technologies to manufacture custom microarray based
on OBD's proprietary probe sets for EpiSwitch(R) Explorer Array
Kit
-- First commercial microarray kit available for high-resolution
3D genome profiling and biomarker discovery
-- Kit accompanied by EpiSwitch(R) Data Portal to enable
powerful, intuitive analytics of research data and access to 3D
genome knowledgebase
-- Launch of the EpiSwitch(R) Explorer Array Kit expands
academic and clinical researcher access to OBD's EpiSwitch(R)
technology platform following the launch of its EpiSwitch(R)CST
(COVID-19 Severity Test)
Oxford, UK - 31 March 2021- Oxford BioDynamics Plc (AIM: OBD,
the Company), a biotechnology company developing precision medicine
tests for personalized healthcare based on the EpiSwitch (R) 3D
genomics platform, and Agilent Technologies (NYSE: A), a global
leader in the life sciences, diagnostics, and applied chemical
markets, have signed a supply and resale agreement for the
manufacture and sale of the new EpiSwitch (R) Explorer Array Kit
("Kit").
Under the terms of the agreement, Agilent will supply a
custom-made SurePrint G3 CGH Microarray for the Kit, incorporating
OBD's proprietary 3D genome probes. OBD has exclusive rights for
supply and distribution of the Kit.
Harnessing the strengths of Agilent's microarray technology and
OBD's 3D genomic recognition algorithms, the EpiSwitch(R) Explorer
Array Kit provides results at a high throughput, with high
resolution in a fraction of the time. The Kit simultaneously
interrogates almost 1 million 3D genomic sites, providing over ten
times more high-value data points than conventional, costly,
time-consuming methods of detection, which are limited by high
noise to signal ratio. This creates a highly reproducible, unbiased
map, which can be used to identify, evaluate, or monitor 3D genomic
biomarkers.
The newly launched Kit, which is for research use only, will
enable a new level of whole genome screening, biomarker discovery,
and profiling of the 3D genome. It can assist researchers by
analyzing the genome's 3D architecture and the crucial role it
plays in gene regulation.
Improved understanding of the 3D genome could have a significant
impact on patient diagnosis, prognosis of disease response, and
determination of treatment options. T he global epigenetics market
size is expected to reach over $22 billion by 2025, with the kits
segment anticipated to experience the greatest growth (>20%
CAGR), driven by this need for biomarker development and accurate
detection for personalized medicine [2].
The EpiSwitch (R) platform has already been used to develop the
recently launched COVID-19 Severity Test, EpiSwitch (R) CST .
Further tests are being developed in other areas including
immuno-oncology response, rheumatoid arthritis and prostate cancer
[3-8].
Dr Jon Burrows, CEO of Oxford BioDynamics, said:
"EpiSwitch(R) is already well validated in pharma biomarker
discovery and has proven capable of stratifying patients for many
biological indications [3-8]. OBD has previously announced the
expansion of its strategic focus [1] to bring the platform to the
precision medicine market, starting with the launch of our COVID-19
Severity Test and the upcoming launch of an IO test. Alongside this
strategy, we are keen that our technology and knowledgebase are
made available for research and development by academic and
clinical researchers worldwide."
He added: "Partnering with industry leader, Agilent, gives
important third-party validation to our technology and working
together will strengthen the commercial offering of our EpiSwitch
(R) Explorer Array Kit to the global research community."
Kevin Meldrum, VP/GM of Agilent Genomics said : "Agilent is the
premier provider of custom microarrays and we are excited to secure
this partnership with Oxford BioDynamics demonstrating how arrays
can enable the development of new technologies, such as
EpiSwitch(R), beyond gene expression and CGH."
To accompany the Explorer Array Kit, OBD will also provide
access to their online EpiSwitch(R) Portal to enable array data
analytics and provide biological context for readouts. This Portal
comprises of two applications:
1. The EpiSwitch(R) Analytical Portal (EAP) - to enable
statistical analysis of 3D-array data with a wide range of
tools
2. The EpiSwitch(R) Data Portal (EDP) - to provide options to
map data to the genome, allowing integration of analysis with other
data types (SNPs, Hi-C, ATAC-Seq Chip-Seq, RNA-Seq, etc.) and
biological interpretation
The EpiSwitch(R) Explorer Array Kit is now available to purchase
from OBD's online store: https://store.oxfordbiodynamics.com .
Here, users can also sign up and access the EpiSwitch suite of
analytical portals. The Kit is provided with EpiSwitch(R)-optimized
sample preparation reagents for analysis of blood, PBMC and primary
cell or cell line samples.
-Ends-
FOR MORE INFORMATION:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20 7408 4090
Broker
Advisory: Edward Mansfield / John More
Broking: Fiona Conroy
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Agnes Stephens OxfordBioDynamics@instinctif.com
/ Katie Duffell / Nathan Billis
NOTES TO EDITORS:
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications. The Company recently
released its first commercial prognostic test, EpiSwitch (R) CST
(Covid Severity Test).
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial team in the US and
a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
Oxford BioDynamics is leveraging its leading technology to
develop a pipeline of tests in a wide range of indications, such as
immuno-oncology, neurodegenerative and autoimmune diseases, to
follow the release of its EpiSwitch (R) CST (Covid Severity
Test).
References
1 - Oxford BioDynamics Plc. (2020). Oxford BioDynamics to expand
strategic focus [Press release]. 15 Dec 2020. Available at:
www.londonstockexchange.com/news-article/OBD/oxford-biodynamics-to-expand-strategic-focus/14792751
2 - ResearchAndMarkets. The Global Market for Epigenetics to
2025: Size, Share & Trends Analysis by Technology, Application
and Product. Accessed Mar 2021. Available at:
https://bwnews.pr/3fv9zp0
3 - Hunter, E., Koutsothanasi, C., et al. (2021). 3D genomic
capture of regulatory immuno-genetic profiles in COVID-19 patients
for prognosis of severe COVID disease outcome. BioRxiv,
2021.03.14.435295. https://doi.org/10.1101/2021.03.14.435295
(prognosis of severe COVID outcomes)
4 - Hunter, E., Potluri, S., et al. (2019). Development and
validation of baseline predictive biomarkers for response to
avelumab in second-line (2L) non-small cell lung cancer (NSCLC)
using EpiSwitch (TM) epigenetic profiling . SITC, J. Immunotherapy
Cancer 7(282) P142.
www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P142_avelumab.pdf
(IO for Avelumab with Pfizer & EMD Serono)
5 - Hunter, E., Potluri, S., et al. (2019). Development and
validation of baseline predictive biomarkers for response to
immuno-checkpoint treatments in the context of multi-line and
multi-therapy cohorts using EpiSwitch (TM) epigenetic profiling.
SITC, J. Immunotherapy Cancer 7(282) P143.
www.oxfordbiodynamics.com/wp-content/uploads/2020/06/SITC2019_P143_multitherapy.pdf
(IO for Multitherapy cohorts with Lyell Immunopharma, Mayo Clinic,
Pfizer & EMD Serono)
6 - Hunter, E., McCord, R., et al. (2020). Comparative molecular
cell-of-origin classification of diffuse large B-cell lymphoma
based on liquid and tissue biopsies. Translational Medicine
Communications, 5(1). https://doi.org/10.1186/s41231-020-00054-1
(prognostic for B cell lymphoma)
7 - Carini, C., Hunter, E., et al. (2018). Chromosome
conformation signatures define predictive markers of inadequate
response to methotrexate in early rheumatoid arthritis. J Trans.
Med, 16(18).
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1387-9
(predictive for inadequate response to MTX in rheumatoid
arthritis)
8 - Alshaker, H., Mills, R., et al. (2021). Chromatin
conformation changes in peripheral blood can detect prostate cancer
and stratify disease risk groups. J Transl Med 19(46).
https://doi.org/10.1186/s12967-021-02710-y (prognostic for
high-risk prostate cancer)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFIFVEVSILVIL
(END) Dow Jones Newswires
March 31, 2021 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024